Skip to content Skip to navigation

Fireside Chat: Treating neurodegeneration and advancing brain resilience

2022 Symposium of the Wu Tsai Neurosciences Institute logo
October 13, 2022 - 3:30pm to 4:15pm
Li Ka Shing Center / Paul Berg Hall or via livestream

This special session will feature Carole Ho - Chief Medical Officer and Head of Development at Denali Therapeutics discussing the current state of development of drug interventions in conversation with Tony Wyss-Coray, Director of the newly established Knight Initiative for Brain Resilience.

Speakers


Carole Ho Chief Medical Officer and Head of Development, Denali Therapeutics

Carole Ho

Denali Therapeutics

Carole Ho is the Chief Medical Officer and Head of Development at Denali Therapeutics, Inc. Carole has built an integrated development organization that is responsible for advancing therapeutic candidates from IND enabling toxicology through Phase 1 to Phase 3 testing. Under Carole’s leadership, Denali has advanced eight programs into clinical development since Denali’s founding in 2015 across therapeutic areas including Rare Disease, Parkinson’s disease, Alzheimer's disease, FTD, ALS, and AutoImmune disease.

Prior to Denali, Carole most recently served as Vice President of Genentech in Early Clinical Development and was responsible for delivery of pivotal trial-ready drug candidates in Neurology, Ophthalmology, Immunology, and Infectious Disease. During her 8-year tenure at Genentech, Carole held roles with leadership responsibility across multiple early- and late-stage clinical programs including Rituxan® for Wegener’s granulomatosis and microscopic polyangiitis and ocrelizumab for Multiple Sclerosis. At Genentech, in collaboration with Banner Health, Carole's team led the initiation of the world's first prevention trial in Alzheimer's disease in participants at risk for dementia due to a genetic mutation.

Carole completed her residency in Neurology at Harvard Medical School at the Massachusetts General Hospital / Brigham and Women’s Hospital, where she also served as Chief Resident. She obtained her M.D. from Cornell University and S.B. in Biochemical Sciences from Harvard College. Prior to her Industry career, Carole was on Faculty in the Department of Neurology at Stanford University. Carole currently serves on the Board of Directors of Beam Therapeutics, NGM Therapeutics, and Target ALS.


Tony Wyss-Coray D.H. Chen Distinguished Professor of Neurology and Neurological Sciences and  Director of the Phil and Penny Knight Initiative for Brain Resilience

Tony Wyss-Coray

Stanford University

Tony Wyss-Coray is the D.H. Chen Distinguished Professor of Neurology and Neurological Sciences and the Director of the Phil and Penny Knight Initiative for Brain Resilience at Stanford University.

His lab studies brain aging and neurodegeneration with a focus on age-related cognitive decline and Alzheimer’s disease. The Wyss-Coray research team discovered that circulatory blood factors can modulate brain structure and function and factors from young organisms can rejuvenate old brains. Current studies focus on the molecular basis of the systemic communication with the brain by employing a combination of genetic, cell biology, and –omics approaches in killifish, mice, and humans.

Wyss-Coray has presented his ideas at Global TED, the Tencent WE Summit, and the World Economic Forum, and he was voted Time Magazine’s “The Health Care 50” most influential people transforming health care in 2018. He co-founded Alkahest Inc. and several other companies targeting Alzheimer’s and neurodegeneration and has been the recipient of an NIH Director’s Pioneer Award, a Zenith Award from the Alzheimer’s Association, and a NOMIS Foundation Award.